ArticleNeuropsychiatric disease and treatment2026
Association Between Glymphatic Dysfunction and Anxiety in Parkinson's Disease: Insights from DTI-ALPS and Choroid Plexus Volume.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06858176 (Research on the Brain Glymphatic System of Parkinson's Disease Patients Based on DTI Technology), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research on the Brain Glymphatic System of Parkinson's Disease Patients Based on DTI Technology
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore glymphatic system function in Parkinson's disease (PD) patients with anxiety using multimodal imaging: diffusion tensor image analysis along the perivascular space (DTI-ALPS), enlarged perivascular space (EPVS) number, and choroid plexus volume (CPV). Patients and Methods: In this prospective observational study, 64 PD patients (34 with anxiety [PD-A] and 30 without anxiety [PD-NA]) and 42 healthy controls (HC) were recruited. All participants underwent clinical assessments for anxiety, depression, cognition, and motor symptoms. DTI-ALPS index, EPVS number, and CPV were compared among the three groups, and a composite model integrating these multimodal metrics was developed.Additionally,a partial correlation analysis was conducted to investigate the relationship between the above three imaging indicators and clinical characteristics in PD-A. Results: Compared to the PD-NA, DTI-ALPS Conclusion: PD patients exhibit cerebral glymphatic dysfunction, which is more severe in those with anxiety. Increased CPV is associated with anxiety, depression, and cognitive decline in PD-A patients. Combining multimodal MRI metrics shows potential clinical utility for evaluating glymphatic function. Trial registration number: NCT06858176.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.